Breakthrough Emactuzumab Phase 3 TANGENT Trial in TGCT: SynOx Pharma Reports Enrollment Completed Ahead of Schedule - OncoDaily SynOx Pharma completes Phase 3 TANGENT trial enrollment for Emactuzumab in TGCT, with top-line results expected in early 2026.

Breakthrough Emactuzumab Phase 3 TANGENT Trial in TGCT: SynOx Pharma Reports Enrollment Completed Ahead of Schedule

@synox-tx.bsky.social

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Emactuzumab #TANGENT #TGCT #SynOx